MOTS-C

Resumen del Protocolo

Resumen conciso del once‑daily regimen.

• Objetivo:Apoyar la función metabólica homeostasis, insulin sensitivity, and age-related physical performance basado en evidencia preclínica.
• Programa:Inyecciones subcutáneas diarias por 8–12 semanas (extend to 16 semanas if desired).
• Rango de dosis:200–1,000 mcg daily with gradual titration over 10 semanas.
• Reconstitución:3.0 mL por vial de 10 mg (~3.33 mg/mL) para medidas precisas de unidades.
• Almacenamiento:Liofilizado y congelado a −20 °C (−4 °F); una vez reconstituido, refrigerar a 2–8 °C (35.6–46.4 °F); evitar congelar–thaw.

Protocolo de Dosis

Enfoque de dosis diaria sugerido based on animal-to-human extrapolation.

• Inicio:200 mcg diarias durante 2 semanas.
• Titration:Aumentar en ~200 mcg cada 2 semanas: 400 mcg (Semanas 3–4), 600 mcg (Semanas 5–6), 800 mcg (Semanas 7–8).
• Dosis Objetivo:Up to 1,000 mcg (1.0 mg) daily by Semanas 9–10+ if well tolerated.
• Frecuencia:Una vez al día (subcutáneo).
• Duración del ciclo:8–12 semanas; optional extension to 16 semanas.
• Momento de aplicación:Any consistent time; rotar sitio de inyeccións.

Pasos para Reconstituir

• Extraer3.0 mLde agua bacteriostática con una jeringa estéril.
• Inyectar lentamente por la pared del vial; evitar que haga espuma.
• Gently swirl/roll until dissolved (do not shake vigorously).
• Label with reconstitution date and refrigerate at2–8 °C (35.6–46.4 °F), protegido de la luz.
• Utilizar en un plazo de7 díasfor optimal potency.

Posibles Beneficios

Observations de la literatura preclínica (no human ensayos clínicos completed to date) :

• Metabolic Health:Mejorars insulin sensitivity and glucose metabolism in mouse models; prevents diet-induced insulin resistance.
• Weight & Fat Reduction:Prevents obesity and reduces visceral fat in obese mice through increased energy expenditure and fat oxidation.
• Post-Menopausal Metabolism:Mitigates metabolic decline in ovariectomized mice; prevents menopause-related fat gain and insulin resistance.
• Physical Performance:Mejorars exercise capacity and counters age-related frailty; old mice ran 2× longer on treadmill tests.
• Organ Protection:Reducirs liver fat accumulation, improves cardiac function, and may support función cognitiva in preliminary studies.
• Bone & Immunity:Promovers osteoblast activity, inhibits osteoclast formation; modulates immune aging and protects pancreatic islet cells in autoimmune diabetes models.
• Safety:No adverse effects reported in estudios preclínicos; human tolerability unknown. A modified analog (CB4211) showed buena tolerabilidad in a Phase 1 trial.

Note: These benefits have been demonstrated only in controlled research settings (mice or cells). Translation to humans requires estudios clínicos.